OAP-101 / Novastra Therapeutics - LARVOL DELTA

OAP-101 autologous whole-tumor antigen system-level immune reprogramming therapy in anti-PD-1-refractory advanced melanoma (ESMO 2026) - No abstract available

Metastases • Melanoma • Oncology • Solid Tumor

Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026 (GlobeNewswire)

P1 data • Melanoma

a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Xingchen Peng

New P1 trial • Oncology • Solid Tumor

a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Xingchen Peng | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor